CELL INTELLIGENCE · 肿瘤细胞治疗研究

多发性骨髓瘤中 IMiDs 免疫调节化合物耐药的认识与应对

Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma.

多发性骨髓瘤 CAR-NK 细胞治疗的最新进展：细胞来源与靶抗原的综合综述

State of the Art of CAR-NK Cell Therapy in Multiple Myeloma: A Comprehensive Review of Cell Sources and Target Antigens.

多发性骨髓瘤 CAR 治疗的靶点

Targets for CAR Therapy in Multiple Myeloma.

复发/难治性多发性骨髓瘤：海湾地区患者的标准治疗管理

Relapsed/refractory multiple myeloma: standard of care management of patients in the Gulf region.

新诊断多发性骨髓瘤的新型药物联合方案：如何改进现有方案？

Novel drug combinations for newly diagnosed multiple myeloma: how can we improve on current regimens?

对 NDMM 患者而言，确定最佳治疗顺序是一项挑战。

多发性骨髓瘤中的 CAR-T 疗法：释放未来

CAR T therapies in multiple myeloma: unleashing the future.

新诊断多发性骨髓瘤的当前治疗与未来展望

Management of Newly Diagnosed Multiple Myeloma Today, and in the Future.

释放 CAR-NK 细胞的潜力：针对 CD38 阳性恶性肿瘤的有前景的现货型治疗策略

Harnessing the Power of CAR-NK Cells: A Promising Off-the-Shelf Therapeutic Strategy for CD38-Positive Malignancies.

体外研究结果表明，抗 CD38 CAR-NK 细胞有潜力作为针对 CD38 阳性恶性肿瘤的现货型治疗策略。

烟酰胺扩增的 CD38 缺失、表达增强型 CD38 嵌合抗原受体的同种异体 NK 细胞靶向多发性骨髓瘤细胞

Nicotinamide-Expanded Allogeneic Natural Killer Cells with CD38 Deletion, Expressing an Enhanced CD38 Chimeric Antigen Receptor, Target Multiple Myelo

埃拉那单抗：首次批准

Elranatamab: First Approval.